Prosecution Insights
Last updated: August 06, 2026

Humabs Biomed SA

3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (67%)
1
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (67%)
§112 only1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GRIZER, CASSANDRA SENN 1 75.0% +0.0%
LY, KRISTINA ELISABETH 1 50.0% +100.0%
JADHAO, SAMADHAN JAISING 1 51.9% +49.5%

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18002844 ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF JADHAO, SAMADHAN JAISING 16d overdue
18253383 ANTIBODIES AGAINST INFLUENZA A VIRUSES LY, KRISTINA ELISABETH

Top Art Units

Art UnitApps
1672 2
1671 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18264408 ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS, HUMAN METAPNEUMOVIRUS AND PNEUMONIA VIRUS OF MICE AND METHODS OF USING THE SAME GRIZER, CASSANDRA SENN 1672 §103 Final Rejection Pending Aug 04, 2023
18253383 ANTIBODIES AGAINST INFLUENZA A VIRUSES LY, KRISTINA ELISABETH 1671 §112Other Non-Final OA Pending May 17, 2023
18002844 ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF JADHAO, SAMADHAN JAISING 1672 §103 Final Rejection 16d overdue Pending Dec 21, 2022

Managing Humabs Biomed SA's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month